title: Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States.
abstract: OBJECTIVE
  After a report from the Women's Health Initiative (WHI) in 2002, a precipitous decline in menopausal hormonal therapy (MHT) use in the United States was linked to a decline in breast cancer incidence rates. Given that MHT use is also associated with increased ovarian cancer risk, we tested whether ovarian cancer incidence rates changed after 2002.
  
  
  METHODS
  Using the North American Association of Central Cancer Registries database (1995 to 2008; N = 171,142 incident ovarian cancers), we applied standard analytic approaches and age-period-cohort (APC) models to estimate ovarian cancer incidence rate changes before (1995 to 2002) and after (2003 to 2008) the WHI report.
  
  
  RESULTS
  Among women age ≥ 50 years, age-standardized ovarian cancer incidence declined by 0.8% per year (95% CI, -1.8% to -0.5% per year) before the WHI announcement; after the WHI report, the rate declined by 2.4% per year (95% CI, -2.5% to -2.2% per year). APC models confirmed an accelerated decline in ovarian cancer incidence after the WHI report, adjusted for age and birth cohort effects. This sudden change was notable among women most likely to have used MHT (ie, women age 50 to 69 years, white women, and residents of regions with highest MHT prescription frequency). The largest changes were found for the endometrioid histologic subtype.
  
  
  CONCLUSIONS
  After a marked reduction in MHT use around 2002, ovarian cancer incidence rates demonstrated an accelerated decline, with the largest changes for endometrioid carcinomas. This strong temporal association, although not proving a causal role of hormones in ovarian carcinogenesis, suggests that future analytic research supporting cancer control efforts should clarify the role of hormonal exposures on the development and behavior of subtypes of ovarian cancer.
authors: National Cancer Institute, Bethesda, MD, MD 20852, USA. yanghan@mail.nih.gov
authors: Hannah P
authors: HP
authors: Yang
authors: William F
authors: WF
authors: Anderson
authors: Philip S
authors: PS
authors: Rosenberg
authors: Britton
authors: B
authors: Trabert
authors: Gretchen L
authors: GL
authors: Gierach
authors: Nicolas
authors: N
authors: Wentzensen
authors: Kathleen A
authors: KA
authors: Cronin
authors: Mark E
authors: ME
authors: Sherman
mesh_terms: D015914:Estrogen Replacement Therapy / Q000379:methods / Q000706:statistics & numerical data*; D005260:Female; D020249:Hormone Replacement Therapy / Q000379:methods / Q000706:statistics & numerical data*; D006801:Humans; D015994:Incidence; D008593:Menopause / Q000187:drug effects; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000453:epidemiology*; D014481:United States / Q000453:epidemiology
references: JAMA. 2004 Jan 7;291(1):47-53
references: 14709575
references: N Engl J Med. 2007 Apr 19;356(16):1670-4
references: 17442911
references: Epidemiology. 2000 Mar;11(2):102-5
references: 11021604
references: Obstet Gynecol. 2004 Nov;104(5 Pt 1):1042-50
references: 15516400
references: J Natl Cancer Inst. 1995 Sep 20;87(18):1359-64
references: 7658496
references: Breast Cancer Res. 2007;9(4):108
references: 17666116
references: Adv Anat Pathol. 2006 Sep;13(5):205-27
references: 16998315
references: Nat Rev Cancer. 2012 Dec;12(12):835-48
references: 23151603
references: Obstet Gynecol. 2010 Nov;116(5):1088-95
references: 20966693
references: Int J Cancer. 2010 Dec 15;127(12):2928-35
references: 21351271
references: Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):594-604
references: 18349277
references: Am J Epidemiol. 1996 Jan 1;143(1):85-91
references: 8533751
references: Breast Cancer Res Treat. 2009 Sep;117(1):223-4
references: 18979196
references: J Natl Cancer Inst. 2002 Oct 16;94(20):1537-45
references: 12381706
references: JAMA. 2009 Jul 15;302(3):298-305
references: 19602689
references: JAMA. 2010 May 5;303(17):1723-8
references: 20442388
references: JAMA. 2002 Jul 17;288(3):321-33
references: 12117397
references: Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):132-9
references: 19124490
references: Cancer. 2009 Feb 1;115(3):531-9
references: 19127543
references: Stat Med. 2000 Feb 15;19(3):335-51
references: 10649300
references: Cancer Prev Res (Phila). 2010 Jun;3(6):696-706
references: 20404000
references: Diagn Histopathol (Oxf). 2008 Aug;14(8):352-365
references: 20953242
references: Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1263-8
references: 21610223
references: J Clin Oncol. 2012 Aug 1;30(22):2739-44
references: 22734032
references: Adv Anat Pathol. 2007 May;14(3):149-77
references: 17452813
references: Ann Intern Med. 2004 Feb 3;140(3):184-8
references: 14757616
references: Biometrics. 1983 Jun;39(2):311-24
references: 6626659
references: Cancer Causes Control. 2011 Aug;22(8):1075-84
references: 21637986
references: N Engl J Med. 1976 Jun 3;294(23):1259-62
references: 1264151
references: J Natl Cancer Inst. 2011 May 4;103(9):714-36
references: 21454908
references: Int J Epidemiol. 1992 Apr;21(2):222-8
references: 1428473
references: J Gen Intern Med. 2005 Nov;20(11):1026-31
references: 16307628